KEVIN GAREY to Female
This is a "connection" page, showing publications KEVIN GAREY has written about Female.
Connection Strength
1.228
-
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial. J Antimicrob Chemother. 2025 Oct 03; 80(10):2719-2726.
Score: 0.037
-
Prebiotics Improve Blood Pressure Control by Modulating Gut Microbiome Composition and Function: A Systematic Review and Meta-Analysis. Nutrients. 2025 Jul 30; 17(15).
Score: 0.036
-
Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025 02 13; 69(2):e0125124.
Score: 0.035
-
Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers. J Infect Dis. 2024 01 12; 229(1):273-281.
Score: 0.032
-
Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023 01 03; 6(1):e2253570.
Score: 0.030
-
Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains. Anaerobe. 2021 Dec; 72:102440.
Score: 0.028
-
Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe. 2021 Aug; 70:102387.
Score: 0.027
-
Vitamin D Assessment Over 48 Weeks in Treatment-Naive HIV Individuals Starting Lopinavir/Ritonavir Monotherapy. Curr HIV Res. 2021; 19(1):61-72.
Score: 0.026
-
A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects. J Antimicrob Chemother. 2020 12 01; 75(12):3635-3643.
Score: 0.026
-
Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. Antimicrob Agents Chemother. 2020 02 21; 64(3).
Score: 0.025
-
PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255. Emerg Microbes Infect. 2020; 9(1):341-347.
Score: 0.025
-
Molecular epidemiology of toxigenic Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. Anaerobe. 2020 Feb; 61:102081.
Score: 0.024
-
Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge. Clin Infect Dis. 2019 05 17; 68(11):1887-1893.
Score: 0.023
-
Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary centre in the USA. J Glob Antimicrob Resist. 2018 12; 15:41-47.
Score: 0.022
-
Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 07; 146(9):1101-1105.
Score: 0.022
-
Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016 Jul; 93(3):286-9.
Score: 0.019
-
In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infect Control Hosp Epidemiol. 2015 Nov; 36(11):1318-23.
Score: 0.018
-
Age-Stratified Treatment Response Rates in Hospitalized Patients with Clostridium difficile Infection Treated with Metronidazole. Antimicrob Agents Chemother. 2015 Oct; 59(10):6113-6.
Score: 0.018
-
Dispensing inhalers to patients with chronic obstructive pulmonary disease on hospital discharge: Effects on prescription filling and readmission. Am J Health Syst Pharm. 2015 Jul 15; 72(14):1204-8.
Score: 0.018
-
Echinocandin use in hospitalized patients: a multi-institutional study. Am J Med Sci. 2015 Apr; 349(4):316-20.
Score: 0.018
-
Expansion of clinical pharmacy through increased use of outpatient pharmacists for anticoagulation services. Am J Health Syst Pharm. 2015 Apr 01; 72(7):568-72.
Score: 0.018
-
Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer. 2015 Jan; 62(1):80-4.
Score: 0.017
-
Host factors and clinical outcomes of Candida colonization in critically ill patients. Mycopathologia. 2015 Feb; 179(1-2):87-93.
Score: 0.017
-
Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS One. 2014; 9(7):e102848.
Score: 0.017
-
FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014 Sep 15; 59(6):819-25.
Score: 0.017
-
Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother. 2014 Jun; 48(6):683-90.
Score: 0.016
-
Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect. 2013 Sep; 85(1):28-32.
Score: 0.016
-
Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection. J Hosp Infect. 2013 Apr; 83(4):294-9.
Score: 0.015
-
Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 01; 69(11):979-84.
Score: 0.015
-
Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci. 2012 Apr; 343(4):277-80.
Score: 0.014
-
Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012 Jun; 56(6):3239-43.
Score: 0.014
-
Crofelemer for the treatment of secretory diarrhea. Expert Rev Gastroenterol Hepatol. 2012 Feb; 6(1):17-23.
Score: 0.014
-
A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy. 2012 Feb; 32(2):129-34.
Score: 0.014
-
Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States. AIDS Res Hum Retroviruses. 2012 May; 28(5):454-9.
Score: 0.014
-
Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai. 2011 Jul; 94(7):863-70.
Score: 0.014
-
Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011 Sep; 66(9):2146-51.
Score: 0.014
-
High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect. 2011 Sep; 79(1):23-6.
Score: 0.014
-
A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis. 2010 Dec 15; 51(12):1406-10.
Score: 0.013
-
Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother. 2010 Sep; 54(9):3717-22.
Score: 0.013
-
Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2009 Mar; 63(3):279-85.
Score: 0.011
-
Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol. 2009 Jan; 43(1):91-3.
Score: 0.011
-
Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20.
Score: 0.011
-
A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect. 2008 Oct; 70(2):142-7.
Score: 0.011
-
Peripartum Clostridium difficile infection: case series and review of the literature. Am J Obstet Gynecol. 2008 Oct; 199(4):332-7.
Score: 0.011
-
Economic benefit of appropriate timing of vancomycin prophylaxis in patients undergoing cardiovascular surgery. Pharmacotherapy. 2008 Jun; 28(6):699-706.
Score: 0.011
-
Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7.
Score: 0.011
-
Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob Agents Chemother. 2008 Feb; 52(2):446-51.
Score: 0.011
-
Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf. 2007 Aug; 16(8):919-27.
Score: 0.010
-
Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):309-14.
Score: 0.010
-
Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. Int J Antimicrob Agents. 2007 May; 29(5):557-62.
Score: 0.010
-
Comparison of risk factors for candidemia versus bacteremia in hospitalized patients. Infection. 2006 Dec; 34(6):322-7.
Score: 0.010
-
Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007 Jan; 51(1):35-9.
Score: 0.010
-
Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther. 2006 Aug; 28(8):1208-1216.
Score: 0.010
-
Risk factors for postoperative chest wound infections due to gram-negative bacteria in cardiac surgery patients. J Chemother. 2006 Aug; 18(4):402-8.
Score: 0.010
-
Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother. 2006 Sep; 58(3):645-50.
Score: 0.010
-
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006 Jul 01; 43(1):25-31.
Score: 0.010
-
Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother. 2006 Jun; 40(6):1030-4.
Score: 0.010
-
Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses. 2006 May; 49(3):226-31.
Score: 0.010
-
Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization. Ann Pharmacother. 2006 Mar; 40(3):381-5.
Score: 0.009
-
Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals. Clin Infect Dis. 2026 Feb 09; 82(1):75-85.
Score: 0.009
-
Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study. Lancet Microbe. 2025 Aug; 6(8):101126.
Score: 0.009
-
Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response. Clin Infect Dis. 2024 07 19; 79(1):15-21.
Score: 0.008
-
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 06 14; 78(6):1462-1472.
Score: 0.008
-
Markers of inflammation in exhaled breath condensate of young healthy smokers. Chest. 2004 Jan; 125(1):22-6.
Score: 0.008
-
Increased Prevalence of Clostridioides difficile Infection Among Pediatric Oncology Patients: Risk Factors for Infection and Complications. Pediatr Infect Dis J. 2024 Feb 01; 43(2):136-141.
Score: 0.008
-
Involvement of immunization-certified pharmacists with immunization activities. Ann Pharmacother. 2004 Feb; 38(2):226-31.
Score: 0.008
-
Validation of a Health-Related Quality of Life Questionnaire in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Phase 3 Randomized Trial. Clin Infect Dis. 2023 02 08; 76(3):e1195-e1201.
Score: 0.008
-
Impact of Clostridioides difficile infection on patient-reported quality of life. Infect Control Hosp Epidemiol. 2022 10; 43(10):1339-1344.
Score: 0.007
-
Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection. Gut Microbes. 2021 Jan-Dec; 13(1):1-18.
Score: 0.007
-
Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest. 2000 Dec; 118(6):1826-7.
Score: 0.007
-
Using the Theory of Planned Behavior to Evaluate Factors That Influence PharmD Students' Intention to Attend Lectures. Am J Pharm Educ. 2020 05; 84(5):7550.
Score: 0.006
-
Whole-genome sequencing of Staphylococcus epidermidis bloodstream isolates from a prospective clinical trial reveals that complicated bacteraemia is caused by a limited number of closely related sequence types. Clin Microbiol Infect. 2020 May; 26(5):646.e1-646.e8.
Score: 0.006
-
Bifidobacterium dentium Fortifies the Intestinal Mucus Layer via Autophagy and Calcium Signaling Pathways. mBio. 2019 06 18; 10(3).
Score: 0.006
-
Characterization of Clostridioides difficile ribotypes in domestic dogs in Rio de Janeiro, Brazil. Anaerobe. 2019 Aug; 58:22-29.
Score: 0.006
-
Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. Antimicrob Agents Chemother. 1999 May; 43(5):1152-5.
Score: 0.006
-
Intravenous azithromycin. Ann Pharmacother. 1999 Feb; 33(2):218-28.
Score: 0.006
-
Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. Infect Control Hosp Epidemiol. 2018 11; 39(11):1322-1329.
Score: 0.006
-
Bacteremia in Patients With Liver Cirrhosis: Prevalence and Predictors of Multidrug Resistant Organisms. J Clin Gastroenterol. 2018 08; 52(7):648-654.
Score: 0.006
-
Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. Clin Infect Dis. 2018 05 17; 66(11):1678-1686.
Score: 0.005
-
Multicentre derivation and validation of a simple predictive index for healthcare-associated Clostridium difficile infection. Clin Microbiol Infect. 2018 Nov; 24(11):1190-1194.
Score: 0.005
-
Investigating inpatient medication administration using the theory of planned behavior. Am J Health Syst Pharm. 2017 Dec 15; 74(24):2065-2070.
Score: 0.005
-
Possible interaction between imipramine and butalbital. Pharmacotherapy. 1997 Sep-Oct; 17(5):1041-2.
Score: 0.005
-
Association between health literacy and 30-day healthcare use after hospital discharge in the heart failure population. Res Social Adm Pharm. 2017 Jul - Aug; 13(4):754-758.
Score: 0.005
-
Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. J Clin Gastroenterol. 2016 09; 50(8):631-7.
Score: 0.005
-
A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob. 2016 Apr 12; 15:22.
Score: 0.005
-
Epidemiology of meningitis with a negative CSF Gram stain: under-utilization of available diagnostic tests. Epidemiol Infect. 2016 Jan; 144(1):189-97.
Score: 0.004
-
Reply to Bauer and Goff. Clin Infect Dis. 2015 Aug 01; 61(3):487-8.
Score: 0.004
-
A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection. PLoS One. 2015; 10(4):e0123405.
Score: 0.004
-
Identification of toxemia in patients with Clostridium difficile infection. PLoS One. 2015; 10(4):e0124235.
Score: 0.004
-
T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015 Mar 15; 60(6):892-9.
Score: 0.004
-
Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol. 2014 Jun; 35(6):667-73.
Score: 0.004
-
Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol. 2014 Apr; 21(4):509-17.
Score: 0.004
-
Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother. 2013 Jun; 57(6):2690-3.
Score: 0.004
-
Clostridium difficile-related death rates in Texas 1999-2005. J Infect. 2009 Nov; 59(5):303-7.
Score: 0.003
-
Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. Pharm World Sci. 2009 Oct; 31(5):565.
Score: 0.003
-
Automated system to identify Clostridium difficile infection among hospitalised patients. J Hosp Infect. 2009 Aug; 72(4):337-41.
Score: 0.003
-
Significant publications on infectious diseases pharmacotherapy in 2007. Am J Health Syst Pharm. 2008 Nov 15; 65(22):e72-9.
Score: 0.003
-
Pharmacist-managed vaccination program increased influenza vaccination rates in cardiovascular patients enrolled in a secondary prevention lipid clinic. Pharmacotherapy. 2007 May; 27(5):729-33.
Score: 0.003
-
Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. J Hosp Infect. 2007 Jan; 65(1):42-6.
Score: 0.002
-
A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol. 2006 May; 101(5):1112-6.
Score: 0.002
-
Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm World Sci. 2005 Apr; 27(2):81-2.
Score: 0.002
-
Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. Clin Transplant. 2001 Oct; 15(5):297-308.
Score: 0.002
-
A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy. 2001 Sep; 21(9):1107-14.
Score: 0.002